WallStSmart

Hyperfine Inc (HYPR)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 237124% more annual revenue ($36.36B vs $15.33M). MDT leads profitability with a 13.2% profit margin vs -226.9%. MDT earns a higher WallStSmart Score of 62/100 (C+).

HYPR

Avoid

23

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -7.66

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HYPR.

MDTUndervalued (+11.4%)

Margin of Safety

+11.4%

Fair Value

$91.83

Current Price

$81.67

$10.16 discount

UndervaluedFair: $91.83Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HYPR1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
82.6%10/10

Revenue surging 82.6% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$103.20B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

HYPR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$158.83M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-101.2%2/10

ROE of -101.2% — below average capital efficiency

Free Cash FlowQuality
$-9.25M2/10

Negative free cash flow — burning cash

MDT2 concerns · Avg: 3.5/10
PEG RatioValuation
1.594/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HYPR

The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 82.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : HYPR

The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Piotroski F-Score.

Key Dynamics to Monitor

HYPR profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

HYPR carries more volatility with a beta of 1.42 — expect wider price swings.

HYPR is growing revenue faster at 82.6% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hyperfine Inc

HEALTHCARE · MEDICAL DEVICES · USA

Hyperfine Inc. is a leading medical technology innovator that has revolutionized imaging diagnostics with the introduction of the first FDA-cleared portable MRI system. This groundbreaking solution enhances accessibility to imaging directly at the point of care, thereby improving patient outcomes and expediting clinical decision-making. By prioritizing cost efficiency and convenience, Hyperfine is well-positioned to capitalize on burgeoning market opportunities, making it an appealing investment for institutional investors interested in transformative healthcare advancements.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?